Swayam Prakash

Dr. Swayam Prakash

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2022 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
Swayam PrakashSwayam Prakash
Swayam Prakash
SSSaugata Sahu
Saugata Sahu
BPBamadeb Patra
Bamadeb Patra
AMAshok Kumar Mishra
Ashok Kumar Mishra

24 May 2023 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NDNisha Rajeswari Dhanushkodi
Nisha Rajeswari Dhanushkodi
Swayam PrakashSwayam Prakash
Swayam Prakash
AQAfshana Quadiri
Afshana Quadiri
LZLatifa Zayou
Latifa Zayou
RSRuchi Srivastava
Ruchi Srivastava
LBLBACHIR BENMOHAMED
LBACHIR BENMOHAMED
Four major mucosal-associated chemokines, CCL25, CCL28, CXCL14, and CXCL17, play an important role in protecting mucosal surfaces from infectious pathogens. However, their role in protection against genital herpes remains to be fully explored. The CCL28 is a chemoattractant for the CCR10 receptor–expressing immune cells and is produced homeostatically in the human vaginal mucosa (VM). In this study, we investigated the role of the CCL28/CCR10 chemokine axis in mobilizing protective antiviral B and T cell subsets into the VM site of herpes infection. We report a significant increase in the frequencies of HSV-specific memory CCR10+CD44+CD8+ T cells, expressing high levels of CCR10, in herpes-infected asymptomatic (ASYMP) women compared with symptomatic women. Similarly, a significant increase in the CCL28 chemokine (a ligand of CCR10), was detected in the VM of herpes-infected ASYMP C57BL/6 mice, associated with the mobilization of high frequencies of HSV-specific effector memory CCR10+CD44+CD62L−CD8+ TEM cells and memory CCR10+B220+CD27+ B cells in the VM of HSV-infected ASYMP mice. Inversely, compared with wild-type C57BL/6 mice, the CCL28 knockout (CCL28−/−) mice (1) appeared to be more susceptible to intravaginal infection and reinfection with HSV type 2, and (2) exhibited a significant decrease in the frequencies of HSV-specific effector memory CCR10+CD44+CD62L−CD8+ TEM cells and of memory CD27+B220+ B cells in the infected VM. These findings suggest a critical role of the CCL28/CCR10 chemokine axis in the mobilization of antiviral memory B and T cells within the VM to protect against genital herpes infection and disease.

21 December 2023 in Journal of Virology
Verified
Journal Article
Open access
LZLatifa Zayou
Latifa Zayou
Swayam PrakashSwayam Prakash
Swayam Prakash
NDNisha Rajeswari Dhanushkodi
Nisha Rajeswari Dhanushkodi
AQAfshana Quadiri
Afshana Quadiri
IIIzabela Coimbra Ibraim
Izabela Coimbra Ibraim
LBLBACHIR BENMOHAMED
LBACHIR BENMOHAMED
The pandemic of the coronavirus disease 2019 (COVID-19) has created the largest global health crisis in almost a century. Low frequencies of functional SARS-CoV-2-specific CD4 + and CD8 + T cells in the lungs of COVID-19 patients have been associated with severe cases of COVID-19. Low levels of T cell-attracting CXCL9, CXCL10, and CXCL11 chemokines in infected lungs may not be sufficient for the migration of CD4 + and CD8 + T cells from circulation into infected lungs. We hypothesize that a coronavirus vaccine strategy that boosts the frequencies of functional SARS-CoV-2-specific CD4 + and CD8 + T cells in the lungs would lead to better protection from COVID-19-like symptoms. In the present study, we designed and pre-clinically tested the safety, immunogenicity, and protective efficacy of a novel multi-epitope/CXCL11 prime/pull mucosal coronavirus vaccine. This prime/pull vaccine strategy consists of intranasal delivery of a lung-tropic adeno-associated virus type 9 vector that incorporates highly conserved human CD4 + and CD8 + cell epitopes of SARS-CoV-2 ( prime ) followed by recruitment of the primed T cells into the lungs using the T cell-attracting chemokine, CXCL-11 ( pull ). We demonstrated that the immunization of HLA-DR*0101/HLA-A*0201/hACE2 triple transgenic mice with this multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine: (i) increased the frequencies of functional CD4 + and CD8 + T EM , T CM , and T RM cells in the lungs and (ii) reduced COVID-19-like symptoms, lowered virus replication, and prevented deaths following challenge with SARS-CoV-2. These findings demonstrate that bolstering the number of functional lung-resident memory CD4 + and CD8 + T cells improved protection against SARS-CoV-2 infection, COVID-19-like symptoms, and death. IMPORTANCE: Although the current rate of SARS-CoV-2 infections has decreased significantly, COVID-19 still ranks very high as a cause of death worldwide. As of October 2023, the weekly mortality rate is still at 600 deaths in the United States alone, which surpasses even the worst mortality rates recorded for influenza. Thus, the long-term outlook of COVID-19 is still a serious concern outlining the need for the next-generation vaccine. This study found that a prime/pull coronavirus vaccine strategy increased the frequency of functional SARS-CoV-2-specific CD4 + and CD8 + memory T cells in the lungs of SARS-CoV-2-infected triple transgenic HLA-DR*0101/HLA-A*0201/hACE2 mouse model, thereby resulting in low viral titer and reduced COVID-19-like symptoms.


27 September 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Swayam PrakashSwayam Prakash
Swayam Prakash
SKSweta Karan
Sweta Karan
YLYassir Lekbach
Yassir Lekbach
DTDelia F. Tifrea
Delia F. Tifrea
CFCesar J. Figueroa
Cesar J. Figueroa
LBLBACHIR BENMOHAMED
LBACHIR BENMOHAMED
Long COVID (LC), also known as post-acute sequelae of COVID-19 infection (PASC), is a heterogeneous and debilitating chronic disease that currently affects 10 to 20 million people in the U.S. and over 420 million people globally. With no approved treatments, the long-term global health and economic impact of chronic LC remains high and growing. LC affects children, adolescents, and healthy adults and is characterized by over 200 diverse symptoms that persist for months to years after the acute COVID-19 infection is resolved. These symptoms target twelve major organ systems, causing dyspnea, vascular damage, cognitive impairments (“brain fog”), physical and mental fatigue, anxiety, and depression. This heterogeneity of LC symptoms, along with the lack of specific biomarkers and diagnostic tests, presents a significant challenge to the development of LC treatments. While several biological abnormalities have emerged as potential drivers of LC, a causative factor in a large subset of patients with LC, involves reservoirs of virus and/or viral RNA (vRNA) that persist months to years in multiple organs driving chronic inflammation, respiratory, muscular, cognitive, and cardiovascular damages, and provide continuous viral antigenic stimuli that overstimulate and exhaust CD4+ and CD8+ T cells. In this review, we (i) shed light on persisting virus and vRNA reservoirs detected, either directly (from biopsy, blood, stool, and autopsy samples) or indirectly through virus-specific B and T cell responses, in patients with LC and their association with the chronic symptomatology of LC; (ii) explore potential mechanisms of inflammation, immune evasion, and immune overstimulation in LC; (iii) review animal models of virus reservoirs in LC; (iv) discuss potential T cell immunotherapeutic strategies to reduce or eliminate persistent virus reservoirs, which would mitigate chronic inflammation and alleviate symptom severity in patients with LC.

1 February 2021 in Chemosphere
Verified
Journal Article
Closed access
Swayam PrakashSwayam Prakash
Swayam Prakash
SPSuraj Kumar Panigrahi
Suraj Kumar Panigrahi
RDRebecca Paulina Dorner
Rebecca Paulina Dorner
MWMartin Wagner
Martin Wagner
WSWido Schmidt
Wido Schmidt
AMAshok Kumar Mishra
Ashok Kumar Mishra